Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / Feb / Also in the News…
Research & Innovations Anterior Segment Cornea Glaucoma Retina

Also in the News…

From new GA treatments to retinoblastoma mutations, these are the news stories and studies that caught our attention this week…

By Alun Evans 2/7/2025 1 min read

Share

Nissangeniss, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons

Preclinical results of a new GA topical treatment. SeaBeLife, a French biotechnology company developing a topical treatment for geographic atrophy (GA), announced positive preclinical efficacy results for SBL03, an ophthalmic gel for non-invasive topical application. SBL03 is presented by the company as a potential alternative to intravitreal injections, directly targeting retinal cell necrosis in GA. Link

Healthcare veteran joins CooperVision. Steven Robins, formerly chief marketing officer and president of North American Vision Care, Bausch + Lomb, has been appointed “President, Americas” of global contact lenses manufacture at CooperVision. “It’s a privilege to join the company that has its sights set on becoming an even greater part of people’s lives through remarkable innovations and partnerships,” said Robins. Link

Glutamine for DED. A recent Signal Transduction & Targeted Therapy study has identified glutamine metabolism as a key therapeutic target for dry eye disease (DED). Researchers found that using a combination of mesenchymal stem cells (MSCs) and thymosin beta-4 (Tβ4) improved DED symptoms by increasing glutamine levels, reducing inflammation, and enhancing ocular surface healing. The study highlights glutaminase 1 (GLS1) inhibition as a promising strategy for developing new DED treatments. Link

Retinoblastoma mutation. Researchers in Mexico have identified a potential gain-of-function mutation in the RB1 gene, challenging Knudson’s two-hit hypothesis of retinoblastoma. They found that the pR552* mutation promotes aggressive tumor growth even when one normal RB1 allele is present, suggesting oncogenic properties rather than simple tumor suppressor loss. This discovery could reshape retinoblastoma diagnostics and treatment strategies, the authors state, highlighting the need for further research into RB1 mutations and their role in cancer development. Link

Mapping Malignant Tumors. A recent IOVS study has mapped the metabolic landscape of eyelid infiltrative basal cell carcinoma (iBCC) using single-cell transcriptomics and spatial metabolomics. The researchers from Sun Yat-Sen University, China, identified eight distinct cell types, with cancer-associated fibroblasts (CAFs) showing altered glycolysis, glutamine, and lipid metabolism – all key drivers of tumor progression. The study highlights metabolic targets like UDPGA, UGDH, and UXS1, offering potential new therapeutic strategies for diagnosing and treating iBCC. Link

About the Author(s)

Alun Evans

More Articles by Alun Evans

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: